Loading…
Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
Purpose: To report findings when dilated fundus examination (DFE) is omitted from follow-up of patients receiving anti-VEGF injections for neovascular age-related macular degeneration (NVAMD). Design: Randomized pilot study. Participants: NVAMD patients with two or more injections of anti-VEGF withi...
Saved in:
Published in: | Clinical ophthalmology (Auckland, N.Z.) N.Z.), 2021-01, Vol.15, p.3401-3417 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c453t-9e113c119c9160c63ce998831d400ddf66435f7321e5c61df31d6c456363e4be3 |
---|---|
cites | cdi_FETCH-LOGICAL-c453t-9e113c119c9160c63ce998831d400ddf66435f7321e5c61df31d6c456363e4be3 |
container_end_page | 3417 |
container_issue | |
container_start_page | 3401 |
container_title | Clinical ophthalmology (Auckland, N.Z.) |
container_volume | 15 |
creator | Solomon, Sharon D Kyerematen, Victoria Qutab, Madiha Wenick, Adam S Wang, Jiangxia Hawkins, Barbara S |
description | Purpose: To report findings when dilated fundus examination (DFE) is omitted from follow-up of patients receiving anti-VEGF injections for neovascular age-related macular degeneration (NVAMD). Design: Randomized pilot study. Participants: NVAMD patients with two or more injections of anti-VEGF within prior six months who were expected to require treatment for at least eight more months. Methods and Interventions: Participants were assigned to either retinal imaging and DFE or retinal imaging without a DFE except at 16 weeks and 32 weeks and at study completion. Outcomes: Primary safety outcomes were change in usual-corrected visual acuity (UCVA) and central subfield thickness (CST). Primary efficacy outcomes included time spent in clinic and patient satisfaction with clinic visits. Results: The 66 participants had mean baseline UCVA of 20/50 in the study eye. Median change in UCVA from baseline to each clinic visit in each arm was "no change". Mean change in CST was less than 15 microns from baseline to any follow-up clinic visit. Time spent in the clinic at follow-up visits averaged 20 minutes less for participants in the Imaging Only group than those in the Full Exam group. More participants in the Imaging Only group were satisfied with the time spent in clinic and with the clinic visits overall than participants in the Full Exam group: means of 71 vs 91 minutes, respectively, per clinic visit. Conclusion: Based on findings from this randomized pilot study, follow-up retina clinic visits for established patients who have NVAMD and are under treatment with intravitreous injection of anti-VEGF agents could be streamlined by implementing longer intervals between DFE and by relying on imaging alone to make most decisions regarding the need for retreatment, thereby reducing the time spent by patients in clinic and increasing their satisfaction with care received, without excess adverse events. Trial Registration: NCT02251366. Keywords: neovascular age-related macular degeneration, anti-VEGF injection, time in clinic |
doi_str_mv | 10.2147/OPTH.S315554 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a9ff6d23695247d6bddab7d9ce49adde</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A675905511</galeid><doaj_id>oai_doaj_org_article_a9ff6d23695247d6bddab7d9ce49adde</doaj_id><sourcerecordid>A675905511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-9e113c119c9160c63ce998831d400ddf66435f7321e5c61df31d6c456363e4be3</originalsourceid><addsrcrecordid>eNpVkstu2zAQRYWiQZOm3fUDCBToykpJ8SFx00JwnkBaG467JmhyZMuQRYeigqY_0t8tZRlBsyI5987BcGaS5BPBFxlh-dfZfHl78UAJ55y9Sc4IyfOUs4K-_e9-mrzvui3GIsNF_i45pYzhgkpxlvwtPaDLutEBLLruW9t36Oq33tWtDrVrO_QTwEapch7Npsv0pq-H5wKCBx120AbkqpjR2-h_AlSuIV3AiPuhTd9ojy5hDS34A_A7KtHcu24PZvBP0EK31u3qP2AnaF43LqCH0NvnD8lJpZsOPh7P8-TX9dVyepvez27upuV9ahinIZVACDWESCOJwEZQA1IWBSWWYWxtJQSjvMppRoAbQWwVFRFTBRUU2AroeXI3cq3TW7X39U77Z-V0rQ4B59dK-1CbBpSWVSVsRoXkGcutWFmrV7mVBpjU1g6sbyNr3692YE1sjtfNK-hrpa03au2eVEFFnpE8Aj4fAd499tAFtXW9b-P_Vcbj7ASmBYmuL6NrrWNVG9BN2HSu6Q_zUqXIucSck8E4GY0mNrzzUL2UQrAadkcNu6OOu0P_AUR2tqk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2562060381</pqid></control><display><type>article</type><title>Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study</title><source>Taylor & Francis Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Solomon, Sharon D ; Kyerematen, Victoria ; Qutab, Madiha ; Wenick, Adam S ; Wang, Jiangxia ; Hawkins, Barbara S</creator><creatorcontrib>Solomon, Sharon D ; Kyerematen, Victoria ; Qutab, Madiha ; Wenick, Adam S ; Wang, Jiangxia ; Hawkins, Barbara S</creatorcontrib><description>Purpose: To report findings when dilated fundus examination (DFE) is omitted from follow-up of patients receiving anti-VEGF injections for neovascular age-related macular degeneration (NVAMD). Design: Randomized pilot study. Participants: NVAMD patients with two or more injections of anti-VEGF within prior six months who were expected to require treatment for at least eight more months. Methods and Interventions: Participants were assigned to either retinal imaging and DFE or retinal imaging without a DFE except at 16 weeks and 32 weeks and at study completion. Outcomes: Primary safety outcomes were change in usual-corrected visual acuity (UCVA) and central subfield thickness (CST). Primary efficacy outcomes included time spent in clinic and patient satisfaction with clinic visits. Results: The 66 participants had mean baseline UCVA of 20/50 in the study eye. Median change in UCVA from baseline to each clinic visit in each arm was "no change". Mean change in CST was less than 15 microns from baseline to any follow-up clinic visit. Time spent in the clinic at follow-up visits averaged 20 minutes less for participants in the Imaging Only group than those in the Full Exam group. More participants in the Imaging Only group were satisfied with the time spent in clinic and with the clinic visits overall than participants in the Full Exam group: means of 71 vs 91 minutes, respectively, per clinic visit. Conclusion: Based on findings from this randomized pilot study, follow-up retina clinic visits for established patients who have NVAMD and are under treatment with intravitreous injection of anti-VEGF agents could be streamlined by implementing longer intervals between DFE and by relying on imaging alone to make most decisions regarding the need for retreatment, thereby reducing the time spent by patients in clinic and increasing their satisfaction with care received, without excess adverse events. Trial Registration: NCT02251366. Keywords: neovascular age-related macular degeneration, anti-VEGF injection, time in clinic</description><identifier>ISSN: 1177-5483</identifier><identifier>ISSN: 1177-5467</identifier><identifier>EISSN: 1177-5483</identifier><identifier>DOI: 10.2147/OPTH.S315554</identifier><identifier>PMID: 34408396</identifier><language>eng</language><publisher>Auckland: Dove Medical Press Limited</publisher><subject>Age ; anti-vegf injection ; Care and treatment ; Clinical Trial Report ; Clinics ; Consent ; Coronaviruses ; COVID-19 ; Macular degeneration ; Medical records ; neovascular age-related macular degeneration ; Patient satisfaction ; Physiological aspects ; Questionnaires ; Retina ; Retinal detachment ; Schedules ; time in clinic ; Vascular endothelial growth factor</subject><ispartof>Clinical ophthalmology (Auckland, N.Z.), 2021-01, Vol.15, p.3401-3417</ispartof><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Solomon et al. 2021 Solomon et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-9e113c119c9160c63ce998831d400ddf66435f7321e5c61df31d6c456363e4be3</citedby><cites>FETCH-LOGICAL-c453t-9e113c119c9160c63ce998831d400ddf66435f7321e5c61df31d6c456363e4be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2562060381?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2562060381?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml></links><search><creatorcontrib>Solomon, Sharon D</creatorcontrib><creatorcontrib>Kyerematen, Victoria</creatorcontrib><creatorcontrib>Qutab, Madiha</creatorcontrib><creatorcontrib>Wenick, Adam S</creatorcontrib><creatorcontrib>Wang, Jiangxia</creatorcontrib><creatorcontrib>Hawkins, Barbara S</creatorcontrib><title>Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study</title><title>Clinical ophthalmology (Auckland, N.Z.)</title><description>Purpose: To report findings when dilated fundus examination (DFE) is omitted from follow-up of patients receiving anti-VEGF injections for neovascular age-related macular degeneration (NVAMD). Design: Randomized pilot study. Participants: NVAMD patients with two or more injections of anti-VEGF within prior six months who were expected to require treatment for at least eight more months. Methods and Interventions: Participants were assigned to either retinal imaging and DFE or retinal imaging without a DFE except at 16 weeks and 32 weeks and at study completion. Outcomes: Primary safety outcomes were change in usual-corrected visual acuity (UCVA) and central subfield thickness (CST). Primary efficacy outcomes included time spent in clinic and patient satisfaction with clinic visits. Results: The 66 participants had mean baseline UCVA of 20/50 in the study eye. Median change in UCVA from baseline to each clinic visit in each arm was "no change". Mean change in CST was less than 15 microns from baseline to any follow-up clinic visit. Time spent in the clinic at follow-up visits averaged 20 minutes less for participants in the Imaging Only group than those in the Full Exam group. More participants in the Imaging Only group were satisfied with the time spent in clinic and with the clinic visits overall than participants in the Full Exam group: means of 71 vs 91 minutes, respectively, per clinic visit. Conclusion: Based on findings from this randomized pilot study, follow-up retina clinic visits for established patients who have NVAMD and are under treatment with intravitreous injection of anti-VEGF agents could be streamlined by implementing longer intervals between DFE and by relying on imaging alone to make most decisions regarding the need for retreatment, thereby reducing the time spent by patients in clinic and increasing their satisfaction with care received, without excess adverse events. Trial Registration: NCT02251366. Keywords: neovascular age-related macular degeneration, anti-VEGF injection, time in clinic</description><subject>Age</subject><subject>anti-vegf injection</subject><subject>Care and treatment</subject><subject>Clinical Trial Report</subject><subject>Clinics</subject><subject>Consent</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Macular degeneration</subject><subject>Medical records</subject><subject>neovascular age-related macular degeneration</subject><subject>Patient satisfaction</subject><subject>Physiological aspects</subject><subject>Questionnaires</subject><subject>Retina</subject><subject>Retinal detachment</subject><subject>Schedules</subject><subject>time in clinic</subject><subject>Vascular endothelial growth factor</subject><issn>1177-5483</issn><issn>1177-5467</issn><issn>1177-5483</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVkstu2zAQRYWiQZOm3fUDCBToykpJ8SFx00JwnkBaG467JmhyZMuQRYeigqY_0t8tZRlBsyI5987BcGaS5BPBFxlh-dfZfHl78UAJ55y9Sc4IyfOUs4K-_e9-mrzvui3GIsNF_i45pYzhgkpxlvwtPaDLutEBLLruW9t36Oq33tWtDrVrO_QTwEapch7Npsv0pq-H5wKCBx120AbkqpjR2-h_AlSuIV3AiPuhTd9ojy5hDS34A_A7KtHcu24PZvBP0EK31u3qP2AnaF43LqCH0NvnD8lJpZsOPh7P8-TX9dVyepvez27upuV9ahinIZVACDWESCOJwEZQA1IWBSWWYWxtJQSjvMppRoAbQWwVFRFTBRUU2AroeXI3cq3TW7X39U77Z-V0rQ4B59dK-1CbBpSWVSVsRoXkGcutWFmrV7mVBpjU1g6sbyNr3692YE1sjtfNK-hrpa03au2eVEFFnpE8Aj4fAd499tAFtXW9b-P_Vcbj7ASmBYmuL6NrrWNVG9BN2HSu6Q_zUqXIucSck8E4GY0mNrzzUL2UQrAadkcNu6OOu0P_AUR2tqk</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Solomon, Sharon D</creator><creator>Kyerematen, Victoria</creator><creator>Qutab, Madiha</creator><creator>Wenick, Adam S</creator><creator>Wang, Jiangxia</creator><creator>Hawkins, Barbara S</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210101</creationdate><title>Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study</title><author>Solomon, Sharon D ; Kyerematen, Victoria ; Qutab, Madiha ; Wenick, Adam S ; Wang, Jiangxia ; Hawkins, Barbara S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-9e113c119c9160c63ce998831d400ddf66435f7321e5c61df31d6c456363e4be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age</topic><topic>anti-vegf injection</topic><topic>Care and treatment</topic><topic>Clinical Trial Report</topic><topic>Clinics</topic><topic>Consent</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Macular degeneration</topic><topic>Medical records</topic><topic>neovascular age-related macular degeneration</topic><topic>Patient satisfaction</topic><topic>Physiological aspects</topic><topic>Questionnaires</topic><topic>Retina</topic><topic>Retinal detachment</topic><topic>Schedules</topic><topic>time in clinic</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Solomon, Sharon D</creatorcontrib><creatorcontrib>Kyerematen, Victoria</creatorcontrib><creatorcontrib>Qutab, Madiha</creatorcontrib><creatorcontrib>Wenick, Adam S</creatorcontrib><creatorcontrib>Wang, Jiangxia</creatorcontrib><creatorcontrib>Hawkins, Barbara S</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Hospital Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Research Library</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Research Library</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Health & Medical Collection</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Clinical ophthalmology (Auckland, N.Z.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Solomon, Sharon D</au><au>Kyerematen, Victoria</au><au>Qutab, Madiha</au><au>Wenick, Adam S</au><au>Wang, Jiangxia</au><au>Hawkins, Barbara S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study</atitle><jtitle>Clinical ophthalmology (Auckland, N.Z.)</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>15</volume><spage>3401</spage><epage>3417</epage><pages>3401-3417</pages><issn>1177-5483</issn><issn>1177-5467</issn><eissn>1177-5483</eissn><abstract>Purpose: To report findings when dilated fundus examination (DFE) is omitted from follow-up of patients receiving anti-VEGF injections for neovascular age-related macular degeneration (NVAMD). Design: Randomized pilot study. Participants: NVAMD patients with two or more injections of anti-VEGF within prior six months who were expected to require treatment for at least eight more months. Methods and Interventions: Participants were assigned to either retinal imaging and DFE or retinal imaging without a DFE except at 16 weeks and 32 weeks and at study completion. Outcomes: Primary safety outcomes were change in usual-corrected visual acuity (UCVA) and central subfield thickness (CST). Primary efficacy outcomes included time spent in clinic and patient satisfaction with clinic visits. Results: The 66 participants had mean baseline UCVA of 20/50 in the study eye. Median change in UCVA from baseline to each clinic visit in each arm was "no change". Mean change in CST was less than 15 microns from baseline to any follow-up clinic visit. Time spent in the clinic at follow-up visits averaged 20 minutes less for participants in the Imaging Only group than those in the Full Exam group. More participants in the Imaging Only group were satisfied with the time spent in clinic and with the clinic visits overall than participants in the Full Exam group: means of 71 vs 91 minutes, respectively, per clinic visit. Conclusion: Based on findings from this randomized pilot study, follow-up retina clinic visits for established patients who have NVAMD and are under treatment with intravitreous injection of anti-VEGF agents could be streamlined by implementing longer intervals between DFE and by relying on imaging alone to make most decisions regarding the need for retreatment, thereby reducing the time spent by patients in clinic and increasing their satisfaction with care received, without excess adverse events. Trial Registration: NCT02251366. Keywords: neovascular age-related macular degeneration, anti-VEGF injection, time in clinic</abstract><cop>Auckland</cop><pub>Dove Medical Press Limited</pub><pmid>34408396</pmid><doi>10.2147/OPTH.S315554</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1177-5483 |
ispartof | Clinical ophthalmology (Auckland, N.Z.), 2021-01, Vol.15, p.3401-3417 |
issn | 1177-5483 1177-5467 1177-5483 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_a9ff6d23695247d6bddab7d9ce49adde |
source | Taylor & Francis Open Access; Publicly Available Content Database; PubMed Central; Coronavirus Research Database |
subjects | Age anti-vegf injection Care and treatment Clinical Trial Report Clinics Consent Coronaviruses COVID-19 Macular degeneration Medical records neovascular age-related macular degeneration Patient satisfaction Physiological aspects Questionnaires Retina Retinal detachment Schedules time in clinic Vascular endothelial growth factor |
title | Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-09T01%3A43%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20Dilated%20Fundus%20Examinations%20Needed%20for%20OCT-Guided%20Retreatment%20of%20Exudative%20Age-Related%20Macular%20Degeneration?%20A%20Prospective,%20Randomized,%20Pilot%20Study&rft.jtitle=Clinical%20ophthalmology%20(Auckland,%20N.Z.)&rft.au=Solomon,%20Sharon%20D&rft.date=2021-01-01&rft.volume=15&rft.spage=3401&rft.epage=3417&rft.pages=3401-3417&rft.issn=1177-5483&rft.eissn=1177-5483&rft_id=info:doi/10.2147/OPTH.S315554&rft_dat=%3Cgale_doaj_%3EA675905511%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c453t-9e113c119c9160c63ce998831d400ddf66435f7321e5c61df31d6c456363e4be3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2562060381&rft_id=info:pmid/34408396&rft_galeid=A675905511&rfr_iscdi=true |